# First-in-Human Single and Multiple Dose of GLPG2222

> **NCT02662452** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** GLPG2222 single dose
- **DRUG:** Placebo single dose
- **DRUG:** GLPG2222 multiple doses
- **DRUG:** Placebo multiple doses

## Key facts

- **NCT ID:** NCT02662452
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2016-04
- **Final completion:** 2016-05
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2016-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02662452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02662452, "First-in-Human Single and Multiple Dose of GLPG2222". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02662452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*